Racial and ethnic differences in preferences for end-of-life treatment.

J Gen Intern Med

Center for Research on Health Care, University of Pittsburgh, 200 Meyran Avenue, Suite 200, Pittsburgh, PA, 15312, USA.

Published: June 2009

Background: Studies using local samples suggest that racial minorities anticipate a greater preference for life-sustaining treatment when faced with a terminal illness. These studies are limited by size, representation, and insufficient exploration of sociocultural covariables.

Objective: To explore racial and ethnic differences in concerns and preferences for medical treatment at the end of life in a national sample, adjusting for sociocultural covariables.

Design: Dual-language (English/Spanish), mixed-mode (telephone/mail) survey.

Participants: A total of 2,847 of 4,610 eligible community-dwelling Medicare beneficiaries age 65 or older on July 1, 2003 (62% response).

Measurements: Demographics, education, financial strain, health status, social networks, perceptions of health-care access, quality, and the effectiveness of mechanical ventilation (MV), and concerns and preferences for medical care in the event the respondent had a serious illness and less than 1 year to live.

Results: Respondents included 85% non-Hispanic whites, 4.6% Hispanics, 6.3% blacks, and 4.2% "other" race/ethnicity. More blacks (18%) and Hispanics (15%) than whites (8%) want to die in the hospital; more blacks (28%) and Hispanics (21.2%) than whites (15%) want life-prolonging drugs that make them feel worse all the time; fewer blacks (49%) and Hispanics (57%) than whites (74%) want potentially life-shortening palliative drugs, and more blacks (24%, 36%) and Hispanics (22%, 29%) than whites (13%, 21%) want MV for life extension of 1 week or 1 month, respectively. In multivariable analyses, sociodemographic variables, preference for specialists, and an overly optimistic belief in the effectiveness of MV explained some of the greater preferences for life-sustaining drugs and mechanical ventilation among non-whites. Black race remained an independent predictor of concern about receiving too much treatment [adjusted OR = 2.0 (1.5-2.7)], preference for dying in a hospital [AOR = 2.3 (1.6-3.2)], receiving life-prolonging drugs [1.9 (1.4-2.6)], MV for 1 week [2.3 (1.6-3.3)] or 1 month's [2.1 (1.6-2.9)] life extension, and a preference not to take potentially life-shortening palliative drugs [0.4 (0.3-0.5)]. Hispanic ethnicity remained an independent predictor of preference for dying in the hospital [2.2 (1.3-4.0)] and against potentially life-shortening palliative drugs [0.5 (0.3-0.7)].

Conclusions: Greater preference for intensive treatment near the end of life among minority elders is not explained fully by confounding sociocultural variables. Still, most Medicare beneficiaries in all race/ethnic groups prefer not to die in the hospital, to receive life-prolonging drugs that make them feel worse all the time, or to receive MV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686762PMC
http://dx.doi.org/10.1007/s11606-009-0952-6DOI Listing

Publication Analysis

Top Keywords

life-prolonging drugs
12
life-shortening palliative
12
palliative drugs
12
racial ethnic
8
ethnic differences
8
greater preference
8
concerns preferences
8
preferences medical
8
treatment life
8
medicare beneficiaries
8

Similar Publications

Objective: This study aimed to determine stakeholders' decision criteria preferences for formulary decisions of cancer drugs in the Ministry of Health. The secondary objective was to identify the outcome measures of interest for assessment of clinical benefits for cancer drugs.

Methods: A survey questionnaire was administered online and as hard copy using purposive sampling to 32 healthcare facilities providing cancer services and the Formulary Management Branch in the Ministry of Health.

View Article and Find Full Text PDF
Article Synopsis
  • AIDS is an incurable disease prevalent in Africa, where patients with low CD4 counts (less than 240) are treated with ARV drugs that can cause serious side effects; understanding the circumstances around these side effects is crucial for effective management.* -
  • A study reviewed hospital records from 2011-2014, analyzing the link between ARV treatment regimens (1A, 2A, 5A) and social/demographic factors; results indicated that side effects were more common in women aged 31-40 and that certain regimens had varying side effects.* -
  • Age, gender, and occupation significantly impacted the occurrence of side effects; older individuals experienced fewer skin rashes, while certain
View Article and Find Full Text PDF

Neuro-ophthalmic complications of modern anti-cancer drugs.

Graefes Arch Clin Exp Ophthalmol

July 2024

Department of Ophthalmology, Greenlane Clinical Centre, Auckland, Auckland, New Zealand.

Purpose: Targeted cancer therapies have been responsible for a dramatic shift in treatment strategies for cancer, and the number of drugs, classes, and indications are continually growing. Neuro-ophthalmic complications of these medications are an uncommon but important subset of adverse events which profoundly impact vision. This review aims to collate studies and reports of known neuro-ophthalmic complications of targeted therapies and describe their management.

View Article and Find Full Text PDF

Importance: Recently, life-prolonging treatments for patients with advanced prostate cancer have been introduced in clinical practice.

Objective: To investigate if the introduction of doublet therapy is associated with changes in survival on a population-basis.

Design, Setting, And Participants: This nationwide population-based cohort study used data from the Prostate Cancer data Base Sweden from 2008 to 2020.

View Article and Find Full Text PDF

Background: Adverse effects (AEs) have been reported with all antiretroviral therapy (ART) medications, and it was among the most common cause for switching or terminating therapy and drug non-adherence. Even though AEs of ART medications are common and to be expected, little study has been conducted on the understanding of patients on the AEs. Therefore, this study aimed to assess patients' knowledge, attitude, and practice (KAP) toward ART medications' AEs and associated factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!